A detailed history of E Fund Management Co., Ltd. transactions in Dexcom Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 6,926 shares of DXCM stock, worth $555,742. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,926
Previous 5,455 26.97%
Holding current value
$555,742
Previous $618,000 24.92%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$64.0 - $116.06 $94,144 - $170,724
1,471 Added 26.97%
6,926 $464,000
Q2 2024

Aug 12, 2024

BUY
$110.31 - $140.45 $36,512 - $46,488
331 Added 6.46%
5,455 $618,000
Q1 2024

May 13, 2024

BUY
$114.22 - $140.1 $3,540 - $4,343
31 Added 0.61%
5,124 $710,000
Q4 2023

Feb 06, 2024

SELL
$75.49 - $124.16 $1,660 - $2,731
-22 Reduced 0.43%
5,093 $631,000
Q3 2023

Nov 13, 2023

BUY
$86.06 - $137.93 $70,483 - $112,964
819 Added 19.06%
5,115 $477,000
Q2 2023

Aug 11, 2023

SELL
$112.47 - $130.98 $85,477 - $99,544
-760 Reduced 15.03%
4,296 $552,000
Q1 2023

May 11, 2023

SELL
$104.0 - $122.92 $29,328 - $34,663
-282 Reduced 5.28%
5,056 $587,000
Q4 2022

Feb 14, 2023

SELL
$84.98 - $122.67 $69,513 - $100,344
-818 Reduced 13.29%
5,338 $604,000
Q3 2022

Nov 14, 2022

BUY
$76.35 - $94.18 $21,683 - $26,747
284 Added 4.84%
6,156 $496,000
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $305,547 - $597,207
4,494 Added 326.12%
5,872 $438,000
Q1 2022

May 12, 2022

BUY
$94.08 - $130.2 $3,386 - $4,687
36 Added 2.68%
1,378 $705,000
Q4 2021

Feb 11, 2022

BUY
$129.87 - $162.82 $1,298 - $1,628
10 Added 0.75%
1,342 $721,000
Q3 2021

Nov 12, 2021

SELL
$106.71 - $143.18 $4,908 - $6,586
-46 Reduced 3.34%
1,332 $728,000
Q1 2021

May 12, 2021

BUY
$84.79 - $104.74 $116,840 - $144,331
1,378 New
1,378 $123,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $31B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.